Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.78 |
| ▸ | GPR3 | P46089 | 1/20 | 0.78 |
| ▸ | KIF11 | P52732 | 11/20 | 0.64 |
| ▸ | TOP2A | P11388 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12219478 | 1.00 | AHR (1.00) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL29380459 | 1.00 | AHR (1.00) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL12219476 | 1.00 | AHR (1.00) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL12240737 | 0.95 | AHR (0.90) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL16195631 | 0.93 | AHR (0.86) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL31453782 | 0.93 | AHR (0.86) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL17072697 | 0.93 | AHR (0.86) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL16290400 | 0.93 | AHR (0.86) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL29406398 | 0.92 | AHR (0.85) | AHRALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL1636528 | 0.92 | AHR (0.85) | AHRALDH1A1HSD17B10GPR3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502342-B2 | Cosmetic composition | MANKE NICOLE (US) | 2025-12-23 | — | — | US | claimed |
| EP-4025643-B1 | THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT | BASF SE (DE) | 2023-08-16 | — | — | EP | claimed |
| US-20220315738-A1 | THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT | BASF SE (DE) | 2022-10-06 | — | — | US | claimed |
| EP-4025643-A1 | THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT | BASF SE (DE) | 2022-07-13 | — | — | EP | claimed |
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2021043859-A1 | THERMOPLASTIC MOLDING COMPOSITIONS THAT RESIST HEAT | BASF SE (DE) | 2021-03-11 | — | — | WO | claimed |
| WO-2019115576-A1 | METHODS OF TREATING HEART FAILURE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-06-20 | — | — | WO | claimed |
| US-20180256617-A1 | METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES | LONGEVICA THERAPEUTICS INC. | 2018-09-13 | — | — | US | claimed |
| US-20160343960-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-11-24 | — | — | US | claimed |
| WO-2016168670-A2 | METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES | LONGEVICA THERAPEUTICS INC. (US) | 2016-10-20 | — | — | WO | claimed |
| US-20100151045-A1 | COMPOSITION AND METHOD FOR REDUCING SIDE-EFFECTS OF INDOLE-3-CARBINOL AND DERIVATIVES | ZHOU JAMES H | 2010-06-17 | — | — | US | claimed |
| EP-1030663-B1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS (US) | 2010-03-10 | — | — | EP | claimed |
| US-20060003027-A1 | Composition and method for reducing side effects of indole-3-carbinol and derivatives | CANON KABUSHIKI KAISHA (JP) | 2006-01-05 | — | — | US | claimed |
| US-6656963-B2 | Inhibits tumor cell growth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-02 | — | — | US | claimed |
| US-20030087946-A1 | Indole-3-carbinol (I3C) derivatives and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-08 | — | — | US | claimed |
| EP-1030663-A4 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS (US) | 2002-06-26 | — | — | EP | claimed |
| US-6369095-B1 | ANTITUMOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | claimed |
| EP-1030663-A1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | Designed Nutritional Products Inc. (US) | 2000-08-30 | — | — | EP | claimed |
| WO-1999017768-A1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 1999-04-15 | — | — | WO | claimed |
| US-5843607-A | Indolocarbazole photoconductors | XEROX CORPORATION (US) | 1998-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087946-A1 | Indole-3-carbinol (I3C) derivatives and methods | CDK6, CDK3, CDKL3 | AHR 1827/4885ALDH1A1 3650/4885HSD17B10 1586/4885 |
| US-20160343960-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | CALCOCO2, CYBA, INTS9 | AHR 132/4885ALDH1A1 2102/4885HSD17B10 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.